Table 1.

Patient demographics

Patient
Age, y
Sex
Cellularity, %
BM blasts, %
Cytogenetics
Therapy
Response 3 mo after therapy
Duration of follow-up
Present condition
1*  53   M   10   <5   +8   ATG   Yes   6 y   Normal counts  
2   72   M   72   <5   +8   None   —   Seen once   —  
3*  67   F   10   <5   +8   ATG   Yes   4 y   Normal counts  
4   57   M   <10   50   +8   None   —   1 mo   Died of infection  
5*  52   M   <10   <5   +8   ATG   Yes   3 y   Normal counts  
6   58   M   50   5   +8   None   —   Seen once   —  
7   57   M   <10   10   +8, 5q-   ATG   No   3 y   Refractory cytopenia  
8   41   M   10   <5   +8   ATG   Yes   3 mo   Died of asthma  
9   66   F   60   5   +8   ATG   No   2 y   Died of hemorrhage  
10   64   M   60   5   +8, 20q-   ATG/CsA   No   1 y   Died of refractory cytopenia  
11   57   M   50   5   +8   None   —   1 y   Stable  
12   72   F   60   <5   +8   None   —   3 mo   Stable thrombocytopenia  
13   62   M   70   <5   +8   None   —   Seen once   —  
14   61   M   60   5   +8   ATG   No   3 y   Died of hemorrhage  
15   51   M   60   12   +8   ATG/CsA   Yes   3 y   Thrombocytopenia  
16   59   F   <10   <5   +8   ATG/CsA   Yes   3.5 y   Normal counts  
17   40   F   30   5   +8   None   —   2 y   Near normal counts  
18   33   F   60   5   +8   ATG   Yes   2.5 y   Normal counts  
19   65   M   50   <5   +8   ATG/CsA   No   4 y   Transfusion dependent  
20   14   F   30   <5   +8, -7   ATG   No   6 mo   Died during BMT  
21   73   M   80   15   +8   ATG   Yes   1 y   Died of infection  
22   49   F   60   5   +8, 5q-   ATG   No   7 y   Died of infection  
23   48   F   10   5   +8, -7   ATG   No   1 y   Died of hemorrhage  
24   55   M   25   <5   +8, -7   ATG/CsA   No   1 y   Underwent BMT  
25   55   M   10   5   +8   None   —   1 y   Stable  
26   52   M   47   <5   +8   ATG/CsA   Yes   2 y   Relapsed, retreated, responded  
27   52   M   <10   15%   +8   BMT   Yes   4 mo   Engrafted  
28*  64   M   10   <5   +8   ATG/CsA   Yes   4 y   Normal counts  
29   60   F   20   <5   +8   ATG/CsA   Yes   2 y   Near normal counts  
30   61   F   80   15   +8   ATG   Yes   6 mo   Died of BM failure  
31   71   M   30   <5   +8   None   —   Seen once   —  
32*  54   M   40   <5   +8   ATG/CsA    24 mo   Relapsed, retreated  
33   54   F   20   <5   +8   ATG/CsA   Yes   26 mo   Normal counts  
34   6   F   <10   <5   +8   ATG   No   42 mo   BMT  
35*  32   M   <10   <5   -7   ATG/CsA   No   3 mo   Died of BM failure  
36   61   M   60   <5   -7   ATG/CsA   Yes   24 mo   Relapsed, responded to 2nd course  
37   71   M   60   <5   -7   ATG/CsA   No   12 mo   Progressed to leukemia  
38*  64   M   60   <5   -7   ATG/CsA   No   7 mo   Died of BM failure  
39   65   M   60   <5   -7   ATG   Yes   3 y   Lost to follow-up  
40   76   M   60   <5   -7   None   —   Seen once   —  
41   67   M   50   <5   -7   None   —   Seen once   —  
42*  60   M   <10   5   -7   ATG/CsA   No   6 mo   Died; transformation to leukemia  
43   48   F   60   20   -7   BMT   —   26 mo   Transformation to leukemia  
44*  23   M   <10   <5   -7   BMT   —   28 mo   Accepted graft  
45   63   F   <10   <5   -7   None   No   Seen once   —  
46   64   F   30   <5   5q-   ATG   No   6 mo   Cytopenia  
47   70   M   30   10   5q-   ATG   No   5 mo   Progressed to leukemia  
48   67   M   50   <5   nl   None   No   12 mo   Died of BM failure  
49   76   M   40   <5   nl   ATG   Yes   16 mo   Died of BM failure  
50   76   F   40   <5   nl   ATG   No   14 mo   Transformation to leukemia  
51   75   M   60   <5   nl   ATG   No   25 mo   Transformation to leukemia  
52
 		 54
 		 M
 		 <10
 		 <5
 		 nl
 		 ATG
 		 No
 		 12 mo
 		 Died of BM failure
 
Patient
Age, y
Sex
Cellularity, %
BM blasts, %
Cytogenetics
Therapy
Response 3 mo after therapy
Duration of follow-up
Present condition
1*  53   M   10   <5   +8   ATG   Yes   6 y   Normal counts  
2   72   M   72   <5   +8   None   —   Seen once   —  
3*  67   F   10   <5   +8   ATG   Yes   4 y   Normal counts  
4   57   M   <10   50   +8   None   —   1 mo   Died of infection  
5*  52   M   <10   <5   +8   ATG   Yes   3 y   Normal counts  
6   58   M   50   5   +8   None   —   Seen once   —  
7   57   M   <10   10   +8, 5q-   ATG   No   3 y   Refractory cytopenia  
8   41   M   10   <5   +8   ATG   Yes   3 mo   Died of asthma  
9   66   F   60   5   +8   ATG   No   2 y   Died of hemorrhage  
10   64   M   60   5   +8, 20q-   ATG/CsA   No   1 y   Died of refractory cytopenia  
11   57   M   50   5   +8   None   —   1 y   Stable  
12   72   F   60   <5   +8   None   —   3 mo   Stable thrombocytopenia  
13   62   M   70   <5   +8   None   —   Seen once   —  
14   61   M   60   5   +8   ATG   No   3 y   Died of hemorrhage  
15   51   M   60   12   +8   ATG/CsA   Yes   3 y   Thrombocytopenia  
16   59   F   <10   <5   +8   ATG/CsA   Yes   3.5 y   Normal counts  
17   40   F   30   5   +8   None   —   2 y   Near normal counts  
18   33   F   60   5   +8   ATG   Yes   2.5 y   Normal counts  
19   65   M   50   <5   +8   ATG/CsA   No   4 y   Transfusion dependent  
20   14   F   30   <5   +8, -7   ATG   No   6 mo   Died during BMT  
21   73   M   80   15   +8   ATG   Yes   1 y   Died of infection  
22   49   F   60   5   +8, 5q-   ATG   No   7 y   Died of infection  
23   48   F   10   5   +8, -7   ATG   No   1 y   Died of hemorrhage  
24   55   M   25   <5   +8, -7   ATG/CsA   No   1 y   Underwent BMT  
25   55   M   10   5   +8   None   —   1 y   Stable  
26   52   M   47   <5   +8   ATG/CsA   Yes   2 y   Relapsed, retreated, responded  
27   52   M   <10   15%   +8   BMT   Yes   4 mo   Engrafted  
28*  64   M   10   <5   +8   ATG/CsA   Yes   4 y   Normal counts  
29   60   F   20   <5   +8   ATG/CsA   Yes   2 y   Near normal counts  
30   61   F   80   15   +8   ATG   Yes   6 mo   Died of BM failure  
31   71   M   30   <5   +8   None   —   Seen once   —  
32*  54   M   40   <5   +8   ATG/CsA    24 mo   Relapsed, retreated  
33   54   F   20   <5   +8   ATG/CsA   Yes   26 mo   Normal counts  
34   6   F   <10   <5   +8   ATG   No   42 mo   BMT  
35*  32   M   <10   <5   -7   ATG/CsA   No   3 mo   Died of BM failure  
36   61   M   60   <5   -7   ATG/CsA   Yes   24 mo   Relapsed, responded to 2nd course  
37   71   M   60   <5   -7   ATG/CsA   No   12 mo   Progressed to leukemia  
38*  64   M   60   <5   -7   ATG/CsA   No   7 mo   Died of BM failure  
39   65   M   60   <5   -7   ATG   Yes   3 y   Lost to follow-up  
40   76   M   60   <5   -7   None   —   Seen once   —  
41   67   M   50   <5   -7   None   —   Seen once   —  
42*  60   M   <10   5   -7   ATG/CsA   No   6 mo   Died; transformation to leukemia  
43   48   F   60   20   -7   BMT   —   26 mo   Transformation to leukemia  
44*  23   M   <10   <5   -7   BMT   —   28 mo   Accepted graft  
45   63   F   <10   <5   -7   None   No   Seen once   —  
46   64   F   30   <5   5q-   ATG   No   6 mo   Cytopenia  
47   70   M   30   10   5q-   ATG   No   5 mo   Progressed to leukemia  
48   67   M   50   <5   nl   None   No   12 mo   Died of BM failure  
49   76   M   40   <5   nl   ATG   Yes   16 mo   Died of BM failure  
50   76   F   40   <5   nl   ATG   No   14 mo   Transformation to leukemia  
51   75   M   60   <5   nl   ATG   No   25 mo   Transformation to leukemia  
52
 		 54
 		 M
 		 <10
 		 <5
 		 nl
 		 ATG
 		 No
 		 12 mo
 		 Died of BM failure
 

BMT indicates bone marrow transplantation; nl, normal.

— indicates patient not treated.

*

Previous history of AA.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal